Compare VFF & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VFF | ENTX |
|---|---|---|
| Founded | 1989 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 357.1M | 147.4M |
| IPO Year | 2013 | 2015 |
| Metric | VFF | ENTX |
|---|---|---|
| Price | $2.84 | $2.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | ★ 796.5K | 360.9K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 184.38 | N/A |
| EPS | 0.08 | ★ 0.22 |
| Revenue | ★ $215,937,000.00 | $42,000.00 |
| Revenue This Year | $12.19 | N/A |
| Revenue Next Year | $15.82 | N/A |
| P/E Ratio | $36.00 | ★ $12.91 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.81 | $0.91 |
| 52 Week High | $4.99 | $4.20 |
| Indicator | VFF | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.89 | 46.68 |
| Support Level | $2.78 | $2.73 |
| Resistance Level | $2.94 | $3.10 |
| Average True Range (ATR) | 0.12 | 0.20 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 38.41 | 10.72 |
Village Farms International Inc owns and operates intensive agricultural greenhouse facilities in British Columbia and Texas, where it produces, markets and sells tomatoes, bell peppers and cucumbers. Its wholly owned subsidiary, Pure Sunfarms, is a vertically integrated licensed producer and supplier of cannabis products sold to other licensed providers and provincial governments across Canada and internationally. The Company's wholly owned subsidiary, Balanced Health, develops and sells, cannabidiol (CBD) based products including ingestible, edible and topical applications. The operating segments of the Company are VF Fresh (Produce), Cannabis Canada, Cannabis U.S., Clean Energy, and Cannabis - Netherlands. The company makes majority of its revenue from the Cannabis Canada segment.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.